Over the last 15 years, we have witnessed a notable shift in oncology drug development activity. Since the U.S. approval of Roche/Genentech’s Herceptin (trastuzumab) in 1998, pharmaceutical…
Physician and Payer Receptivity to Novel Oral and Biologic Agents vs. Biosimilars – A Survey of Dermatologists and Managed Care Organization Pharmacy and Medical Directors For many years,…
A Survey of Medical Oncologists and Interviews with Payers in the EU5 Hepatocellular carcinoma (HCC), thyroid cancer, gastrointestinal stromal tumor (GIST), and neuroendocrine tumors (NETs) fall…
Pancreatic cancer (PaC) is one of the most aggressive and highly lethal solid malignancies, with a 5-year survival of only 5%. Treatment of PaC is largely dependent on tumor size and location…
Where Are the Remaining Areas of Opportunity for Emerging Non-TNF Biologics and Oral Agents in the Increasingly Crowded Psoriatic Arthritis Market? The availability of tumor necrosis factor alpha…
Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs? Nine biologics are approved to treat rheumatoid arthritis (RA),…
Amid Effective TNF-α Inhibitors, What Clinical Improvements Do Rheumatologists and Payers Expect from Emerging Therapies with a Different Mechanism of Action? Axial spondyloarthritis (Ax SpA) is…
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
What Improvements Do Physicians and Payers Expect from Emerging Therapies? Owing to a lack of specific symptoms, the majority of patients with ovarian cancer (CaO) present at an advanced stage of…
How Are Payers Reacting to Elevated Costs and How Will the Cost Trend Impact Specific Brands? The nation’s healthcare payers are using multilayered cost and utilization control strategies to rein…
Last Updated 15 December 2014 Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…
Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…
Last Updated 15 December 2014 Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…
Psoriasis is a chronic inflammatory skin disorder that, although non-life-threatening, can have a major impact on patients’ quality of life depending on its severity and location on the body. The…
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…